Journal
PLACENTA
Volume 86, Issue -, Pages 1-3Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2019.08.001
Keywords
Anti-angiogenic factors; sFlt-1 e15a; sFlt-1; PlGF; Preeclampsia
Funding
- Glyn White Research Fellowship from the Royal Australian and New Zealand College of Obstetricians and Gynaecologists
- Thermo Fisher Scientific
Ask authors/readers for more resources
Placental growth factor (PlGF), total soluble fms-like tyrosine-kinase 1 (sFlt-1) and its placental-specific variant, sFlt-1 e15a, show promise as biomarkers for the prediction and diagnosis of preeclampsia. This study describes the degradation of PlGF, sFlt-1 and sFlt-1 e15a within maternal serum and plasma to assist clinical implementation. Whole blood was refrigerated at 4 degrees C for up to 48 h prior to centrifugation for isolation of plasma and serum. PlGF and sFlt-1 were quantified using the B.R.A.H.M.S Kryptor Compact PLUS; sFlt-1 e15a via a custom ELISA. All three analytes are stable for at least 48 h at 4 degrees C. Serum and plasma performed comparably.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available